Charles B O'Keeffe Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 2 days, 10 hours ago
Charles B O'Keeffe has an estimated net worth of at least $16.9 million*, as of July 9, 2025. They own 732,470 shares of CPRX stock. They have sold 87,985 shares of CPRX stock since 2021, for an estimated $1.4 million.
Charles B O'Keeffe $CPRX SEC Form 4 Insider Trading
Charles B O'Keeffe has filed a total of 1 insider trades in $CPRX since 2021. Their most recent trade was a sale of 87,985 shares, made on Nov 15, 2022. Their largest trade was a sale of 87,985 shares, made on Nov 15, 2022. We estimate that they now own 732,470 shares of $CPRX, worth an estimated $15.4 million.
Insider Trading at $CPRX
There have been a total of 120 insider trades reported at $CPRX since 2021, with 0 shares purchased and 6.8 million shares sold. The most active insider traders in $CPRX stock have been Alicia Grande, Patrick J Mcenany, and Gary Ingenito. The most recent trade was a sale of 2,324 shares reported by Preethi Sundaram (Chief Strategy Officer), made on Jun 10, 2025.
History of Insider Stock Trades by Charles B O'Keeffe
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
CPRX
|
Sale | 87,985 | Nov 15, 2022 | Nov. 17, 2022, 6:01 p.m. |
$CPRX Executives and Stock Owners with Insider Trades
-
Alicia Grande, VP, Treasurer and CFO
-
Patrick J Mcenany, President and CEO
-
Gary Ingenito, Chief Med. & Reg. Officer
-
Carmen Jeffrey Del, Chief Commercial Officer
-
Steve Miller, Chief Operating Officer
-
Brian Elsbernd, Chief Compliance/Legal Officer
-
Preethi Sundaram, Chief Strategy Officer
-
Steve Miller, Chief Op. & Scientific Officer
-
Gary Ingenito, Chief Medical & Reg. Officer
-
Gary Ingenito, Chief Medical Officer
-
Richard J Daly, President and CEO
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.